Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
Nefrología (Madrid) ; 43(3): 351-359, may.-jun. 2023. graf, tab
Article in English | IBECS | ID: ibc-220040

ABSTRACT

Background: Oxidative stress increases oxidizability of apolipoprotein-B containing lipoproteins and decreases paraoxonase (PON) activity in hemodialysis (HD) patients and plays an important part in the development of atherosclerotic cardiovascular diseases. In HD patients, plasma ascorbic acid (AA) levels are decreased either due to the loss by hemodialysis membranes or due to malnutrition and contribute to the imbalance of antioxidant defense mechanisms. We hypothesized that long-term ascorbic acid (AA) supplementation recovers oxidizability of lipoproteins in HD patients by reinforcing PON activity. Methods: Twenty-nine adult patients were treated with 100mg and 500mg AA at the end of each HD session thrice a week for two consecutive 16 weeks-periods, respectively. Blood samples were obtained before the first HD session and prior to the first HD sessions following the 100mg AA-supplemented and the 500mg AA-supplemented periods. Results: PON activities were significantly increased after 100mg (p<0.05) and 500mg AA (p<0.001) supplementation periods compared to the basal level. Apo-B lipoprotein oxidizability (Δ-MDA) was significantly decreased after 500mg AA supplementation compared to both basal (p<0.05) and 100mg AA supplementation periods (p<0.05). Plasma AA concentrations were negatively correlated with Δ-MDA levels (R=−0.327; p<0.01). Conclusion: Our results suggest that long-term parenteral 500mg AA supplementation improves PON activity alleviating apo B-containing lipoproteins oxidizability in HD patients. (AU)


Antecedentes: El estrés oxidativo aumenta la susceptibilidad a la oxidación de las apolipoproteínas-B que contienen lipoproteínas y reduce la actividad de paraoxonasa (PON) en pacientes de hemodiálisis (HD) formando un papel importante en el desarrollo de enfermedades arterioescleróticas cardiovasculares. En pacientes de HD, los niveles de ácido ascórbico (AA) plasmático disminuyen debido a la pérdida por membranas de hemodiálisis o por desnutrición, y contribuye al desequilibrio de los mecanismos de defensa antioxidantes. Nuestra hipótesis es que a largo plazo la suplementación con AA recupera la susceptibilidad a la oxidación de las lipoproteínas en pacientes de HD al reforzar la actividad de PON. Métodos: Se trataron 29 pacientes adultos con 100 y 500mg de AA al final de cada sesión de HD/3 veces por semana/durante 2 períodos consecutivos de 16 semanas, respectivamente. Se obtuvieron muestras de sangre antes de la primera sesión de HD y previo a las primeras sesiones de HD luego de los 100mg suplementados con AA y los periodos suplementados con 500mg de AA. Resultados: Las actividades de PON aumentaron significativamente después de los periodos de suplementación de 100mg (p<0,05) y de 500mg de AA (p<0,001) comparados con el nivel base. La susceptibilidad a la oxidación de la lipoproteína apoB (Δ-MDA) disminuyó significativamente luego de la suplementación de 500mg de AA en comparación con períodos de valores base (p<0,05) y los de 100mg de AA (p<0,05). La correlación entre las concentraciones de plasma AA y los niveles de Δ-MDA resultó negativa (R=−0,327; p<0,01). Conclusión: Nuestros resultados sugieren que la suplementación parenteral a largo plazo de 500mg de AA mejora la actividad de PON mitigando la susceptibilidad a la oxidación de las lipoproteínas que contienen apoB en pacientes en HD. (AU)


Subject(s)
Humans , Male , Female , Young Adult , Adult , Middle Aged , Aged , Oxidative Stress , Ascorbic Acid , Dietary Supplements/adverse effects , Renal Dialysis , Apolipoproteins B , Aryldialkylphosphatase
2.
Nefrologia (Engl Ed) ; 43(3): 351-359, 2023.
Article in English | MEDLINE | ID: mdl-36494280

ABSTRACT

BACKGROUND: Oxidative stress increases oxidizability of apolipoprotein-B containing lipoproteins and decreases paraoxonase (PON) activity in hemodialysis (HD) patients and plays an important part in the development of atherosclerotic cardiovascular diseases. In HD patients, plasma ascorbic acid (AA) levels are decreased either due to the loss by hemodialysis membranes or due to malnutrition and contribute to the imbalance of antioxidant defense mechanisms. We hypothesized that long-term ascorbic acid (AA) supplementation recovers oxidizability of lipoproteins in HD patients by reinforcing PON activity. METHODS: Twenty-nine adult patients were treated with 100mg and 500mg AA at the end of each HD session thrice a week for two consecutive 16 weeks-periods, respectively. Blood samples were obtained before the first HD session and prior to the first HD sessions following the 100mg AA-supplemented and the 500mg AA-supplemented periods. RESULTS: PON activities were significantly increased after 100mg (p<0.05) and 500mg AA (p<0.001) supplementation periods compared to the basal level. Apo-B lipoprotein oxidizability (Δ-MDA) was significantly decreased after 500mg AA supplementation compared to both basal (p<0.05) and 100mg AA supplementation periods (p<0.05). Plasma AA concentrations were negatively correlated with Δ-MDA levels (R=-0.327; p<0.01). CONCLUSION: Our results suggest that long-term parenteral 500mg AA supplementation improves PON activity alleviating apo B-containing lipoproteins oxidizability in HD patients.

3.
Ir J Med Sci ; 191(6): 2777-2783, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35067861

ABSTRACT

BACKGROUND: Among one of the common hereditary causes of chronic kidney disease is autosomal-dominant polycystic kidney disease (ADPKD), and its incidence rate is reported as one between 500 and 1.000 individuals. The most common complications of ADPKD are hypertension (HT) and end-stage renal disease (ESRD). HT occurring in the early stage of ADPKD leads to deteriorations in renal function. AIMS: It was aimed to investigate the ischemia-modified albumin (IMA) levels and the effect of renin-angiotensin-aldosterone system (RAAS) blockers on serum IMA levels in patients with ADPKD. METHODS: One hundred and fifteen patients were included as ADPKD (n = 50), HT (n = 35), and healthy control (HC) groups (n = 30). Patients with ADPKD and HT were divided into two subgroups as RAAS blocker-users and non-users. RESULTS: Serum IMA levels were detected as 0.42 (0.17-0.80) in ADPKD and 0.28 (0.04-0.51) in HT and 0.36 (0.22-0.56) in HC groups as absorbance units (ABSU), and the highest serum IMA level was seen in Group ADPKD. Serum IMA levels were 0.33 ± 0.14 in RAAS blocker-users and 0.41 ± 0.11 ABSU in non-users with ADPKD. Serum IMA levels were witnessed to be significantly lower in RAAS blocker-users in Groups ADPKD (p = 0.038) and HT (p = 0.004), compared to non-users. Given basal and 6-month values of those with ADPKD, the levels of serum IMA within 6 months were significantly lower (p = 0.002). CONCLUSIONS: We consider that serum IM levels should be assessed in oxidative stress (OS)-related conditions, such as ADPKD, and RAAS blockers may be effective in reducing serum IMA levels in ADPKD and HT patients.


Subject(s)
Hypertension , Polycystic Kidney, Autosomal Dominant , Humans , Renin-Angiotensin System , Polycystic Kidney, Autosomal Dominant/complications , Polycystic Kidney, Autosomal Dominant/drug therapy , Polycystic Kidney, Autosomal Dominant/epidemiology , Biomarkers , Serum Albumin/pharmacology
4.
World J Urol ; 39(10): 3963-3969, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33890144

ABSTRACT

PURPOSE: Shock wave lithotripsy (SWL) is the first option in the treatment of pediatric kidney stones; however, optimal frequency is still uncertain. The aim of this study was to compare low frequency [60 shocks per minute (SWs/min)] and intermediate frequency [90 SWs/min] in terms of lithotripsy success, complications, cardiac arrhythmia, anesthesia time, secondary procedures, and efficiency quotient (EQ) in children. METHODS: Seventy-eight consecutive children who received SWL for radiopaque renal stones between July 2016 and January 2020 were randomly divided into two groups: Group 60 (SWL frequency: 60 SWs/min) and Group 90 (SWL frequency: 90 SWs/min). After exclusion (remaining 71 children), Group 60 (n = 38) and Group 90 (n = 33) were compared using univariate analysis. RESULTS: The median age of children (37 girls, 34 boys) was 5 (1-16) years. Patient demographics and stone features were similar between the groups. Success rate after the last SWL session was 81.6% (n = 31) for Group 60 and 87.9% (n = 29) for Group 90 (p = 0.527). Stone-free rate after the first, second, and third sessions was 42.1%, 18.4%, and 21.1% for Group 60 and 48.5%, 27.3%, and 12.1% for Group 90, respectively. Additional treatment rate was similar between the groups. In Group 60, the EQ was 57.83, and it was 64.07 in Group 90. Median total anesthesia time was significantly longer in Group 60 (74.5 min) than in Group 90 (32 min; p < 0.001). CONCLUSION: Intermediate frequency and low-frequency pediatric SWL have similar success rates; however, intermediate-frequency SWL has a shorter anesthesia time.


Subject(s)
Kidney Calculi/therapy , Lithotripsy/methods , Adolescent , Arrhythmias, Cardiac/epidemiology , Child , Child, Preschool , Conscious Sedation , Female , Humans , Infant , Male , Time Factors , Treatment Outcome
5.
Nutr Cancer ; 73(2): 339-349, 2021.
Article in English | MEDLINE | ID: mdl-32475178

ABSTRACT

Increased risk of pancreatic cancer may be associated with consumption of sugar containing foods. The aim of this study was to evaluate the effect of peach nectar containing high fructose corn sirup (HFCS) consumption in a pancreatic carcinogenesis rat model induced by 7,12-Dimethyl benzanthracene (DMBA). Fifty-day-old male Sprague Dawley rats were fed with peach nectar containing HFCS + chow, peach nectar containing sucrose + chow and only chow. After 8 mo, feeding period, each group was divided into two subgroups, in which the rats were implanted with DMBA and no DMBA (sham). Histologic specimens were evaluated according to the routine tissue processing protocol. The animals with ad libitum access to pn-HFCS, pn-sucrose and chow (only) showed significant differences in chow consumption and glucose level. Necropsy and histopathologic findings showed tumor formation in the entire group treated with DMBA. Excluding one rat in chow group, which was classified as poorly differentiated type, the others were classified as moderately differentiated pancreatic ductal adenocarcinoma (PDAC). This study demonstrated that daily intake of HFCS did not increase body weight and there was no effect of peach nectar consumption on the development of PDAC induced by DMBA in rats.


Subject(s)
Carcinoma, Pancreatic Ductal , High Fructose Corn Syrup , Pancreatic Neoplasms , 9,10-Dimethyl-1,2-benzanthracene/toxicity , Animals , Carcinoma, Pancreatic Ductal/chemically induced , Fructose , Male , Pancreatic Neoplasms/chemically induced , Rats , Rats, Sprague-Dawley , Zea mays
6.
Clin Exp Nephrol ; 23(10): 1250-1256, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31250147

ABSTRACT

OBJECTIVES: Low fetuin-A levels in hemodialysis patients can be associated with development of vascular and valvular calcifications. The mechanisms underlying vascular and valvular calcifications are multifactorial. There are a few studies showing the relationship between low fetuin-A levels and valvular calcification after kidney transplantation. We aimed to evaluate the association between serum fetuin-A levels and valvular calcification in kidney transplant recipients. METHODS: The cardiac valvular calcification was assessed by echocardiography in 56 recipients. Patients were divided into two groups as those with (n = 11) and without (n = 45) aortic and/or mitral valve calcification. The extent of valvular calcification was visually assessed according to the standard visual score method: moderately (multiple larger spots) and heavily calcified (extensive thickening and calcification) of all cusps. Serum fetuin-A levels were measured. RESULTS: The demographic features of both groups were comparable. There was no significant difference between regular physical exercise (63.6% vs. 55.6%), obesity (18.2% vs. 17.8%), abdominal obesity (54.5% vs. 46.7%), smoking (0% vs. 13.3%), hypertension (63.6% vs. 68.9%), left ventricular hypertrophy (45.5% vs. 33.3%) and diabetes mellitus (9.1% vs. 20%) ratios in groups with or without valvular calcification, respectively (p > 0.05). Fetuin-A levels of both groups did not differ. Fetuin-A levels positively correlated with serum creatinine (r 0.326, p = 0.014), and negatively correlated with estimated glomerular filtration rate (r - 0.297, p = 0.026). CONCLUSIONS: We could not find a relationship between serum fetuin-A levels and valvular calcification in kidney recipients. In this population, further studies are needed to assess the role of serum fetuin-A in valvular calcification.


Subject(s)
Calcinosis/blood , Heart Valve Diseases/blood , Kidney Transplantation , alpha-2-HS-Glycoprotein/analysis , Adult , Calcinosis/diagnostic imaging , Calcium/blood , Creatinine/blood , Echocardiography , Female , Glomerular Filtration Rate , Heart Valve Diseases/diagnostic imaging , Humans , Male , Middle Aged , Negative Results , Risk Factors
7.
Acta Cardiol ; 73(1): 85-90, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28899213

ABSTRACT

BACKGROUND: This study examined whether the serum PON1 activity is different in patients with ischaemic dilated cardiomyopathy (IDCM) and nonischaemic dilated cardiomyopathy (NDCM) and the relation between the serum PON1 activity and serum pro-BNP levels. METHODS AND RESULTS: In this study, we enrolled 60 patients with left ventricular systolic failure (New York Heart Association [NYHA] class III-IV) and a left ventricular ejection fraction (EF) < 40% as determined by echocardiography and 30 healthy subjects. The patients with systolic heart failure were divided into two groups: patients with IDCM and patients with NDCM. Blood samples were obtained to measure the serum PON1 activity and the serum pro-BNP levels. The median serum PON1 activities were lower among the patients with IDCM or with NDCM compared with the control subjects (p < .001, p = .043, respectively). Compared with the control subjects, the patients with IDCM or with NDCM had higher serum pro-BNP levels (p < .001, p < .001, respectively). The serum PON1 activity was negatively correlated with the serum pro-BNP levels in patients with IDCM (r = -0.548, p < .001). The area under the ROC curve of the serum PON1 activity was 0.798. Using a serum PON1 activity of 201.3 U/L as a cut-off value, the sensitivity was 86.84% and specificity was 66.67% for the diagnosis of IDCM. CONCLUSIONS: In this study, the serum PON1 activity was significantly reduced in the patients with IDCM or with NDCM compared with the control subjects. The serum PON1 activity of the patients with IDCM was negatively correlated with the serum pro-BNP levels.


Subject(s)
Aryldialkylphosphatase/blood , Cardiomyopathy, Dilated/enzymology , Myocardial Ischemia/enzymology , Biomarkers/blood , Cardiomyopathy, Dilated/diagnosis , Cardiomyopathy, Dilated/physiopathology , Disease Progression , Echocardiography , Electrocardiography , Female , Humans , Male , Middle Aged , Myocardial Ischemia/diagnosis , Myocardial Ischemia/physiopathology , Stroke Volume/physiology
8.
Metab Syndr Relat Disord ; 15(5): 220-225, 2017 06.
Article in English | MEDLINE | ID: mdl-28394183

ABSTRACT

AIM: The mitogenic potential of analog insulins due to their different insulin-like growth factor-1 (IGF1) receptor affinity is a situation that causes concern related to cancer risk. We aimed to examine the changes in the serum IGF1 levels formed by insulin glargine and detemir in the insulin-naive type 2 diabetic patients. METHODS: The serum total IGF1 levels of the 62 insulin-naive type 2 diabetic patients were studied before and after 12 weeks of the started treatment with basal insulin analogs. Twenty-two and twenty patients (Group I and II) using the single-dose and double-dose insulin detemir and twenty patients (Group III) using insulin glargine were evaluated. RESULTS: In Group I and Group II, the average 8.5% and 0.1% increases and in the Group III, 6.5% decreases were determined in the IGF1 values. The IGF1 changes were significant in the men but not in the women. CONCLUSION: In our study, it was determined that the insulin glargine depressed the serum IGF1 levels much more when compared to the insulin detemir. This result can be evaluated as the in vivo reflection of the in vitro findings related to the fact that the IGF1 receptor affinity of the glargine is higher.


Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin Detemir/administration & dosage , Insulin Glargine/administration & dosage , Insulin-Like Growth Factor I/metabolism , Adult , Aged , Biomarkers/blood , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Down-Regulation , Female , Glycated Hemoglobin/metabolism , Humans , Hypoglycemic Agents/adverse effects , Insulin Detemir/adverse effects , Insulin Glargine/adverse effects , Male , Middle Aged , Time Factors , Treatment Outcome
9.
Ren Fail ; 38(10): 1639-1646, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27764985

ABSTRACT

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with chronic kidney disease (CKD) including kidney transplant recipients (KTR). Secondary lipid metabolism disorders, endothelial dysfunction, and inflammation enhance the risk of CVD development in these patients. The aim of the present study was to investigate the lipid profile, adiponectin, leptin, nitric oxide (NO), and high sensitivity C-reactive protein (hs-CRP) levels in KTR and to compare these parameters with those of the patients with chronic renal failure (CRF), hemodialysis (HD) patients, and healthy controls. METHODS: Serum adiponectin and leptin levels were measured by radioimmunoassay; hs-CRP was determined immunoturbidimetrically. Determination of NO was based on the Griess reaction. RESULTS: Compared with the control group, serum NO and adiponectin levels were significantly higher in the KTR, CRF, and HD groups; hs-CRP levels were significantly higher in the KTR and HD groups; leptin levels were significantly higher in the KTR. In addition, serum NO level was significantly higher in the KTR compared to CRF cases. Adiponectin correlated positively with high density lipoprotein-cholesterol in the control and patient groups. A positive correlation was observed between hs-CRP and NO in the KTR and the patients with CRF. Serum adiponectin levels were inversely correlated with hs-CRP and leptin in the HD group. CONCLUSION: KTR suffer from inflammation and accompanying changes in levels of adipocytokines and NO which contribute to the increased risk of CVD in these patients.


Subject(s)
Cardiovascular Diseases/epidemiology , Kidney Failure, Chronic/therapy , Kidney Transplantation , Renal Dialysis , Adiponectin/blood , Adult , Biomarkers/blood , C-Reactive Protein/analysis , Cardiovascular Diseases/mortality , Case-Control Studies , Female , Humans , Inflammation/blood , Leptin/blood , Male , Middle Aged , Nitric Oxide/blood , Transplant Recipients , Turkey
10.
Acta Cardiol ; 71(2): 185-90, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27090040

ABSTRACT

OBJECTIVES: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) appears to be involved in atherosclerotic plaque vulnerability and rupture. In this study, we aimed to evaluate the utility of serum LOX-1 levels in the diagnosis and assessment of left ventricular systolic HF and LOX-1's relationship with serum pro-brain natriuretic peptide (NT-proBNP). DESIGN AND SETTINGS: This was a cross-sectional study of all eligible patients admitted to the department of cardiology of the University Hospital between July 2011 and April 2012. METHODS: Fifty-five patients with a diagnosis of systolic heart failure and 25 patients without systolic HF were enrolled in this study. Serum C-reactive protein, NT-proBNP, and LOX-1 were studied. RESULTS: Serum LOX-1 and NT-proBNP levels were significantly higher in the heart failure group and showed a positive correlation with NT-proBNP and negative correlations with left ventricular ejection fraction (EF). In addition, LOX-1 levels in patients with ischaemic cardiomyopathy were significantly higher, while they were similar in patients with dilated cardiomyopathy compared to control subjects. CONCLUSION: Our study demonstrates the utility of the serum LOX-1 levels in the diagnosis of left ventricular systolic heart failure. LOX-1 may have a place in the diagnosis of heart failure, in particular in patients with ischaemic cardiomyopathy.


Subject(s)
Heart Failure, Systolic , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Scavenger Receptors, Class E/blood , Ventricular Dysfunction, Left/physiopathology , Aged , Cross-Sectional Studies , Female , Heart Failure, Systolic/blood , Heart Failure, Systolic/diagnosis , Heart Failure, Systolic/physiopathology , Humans , Male , Middle Aged , Prognosis , Reproducibility of Results , Statistics as Topic , Stroke Volume , Turkey
11.
J Diabetes Res ; 2015: 807891, 2015.
Article in English | MEDLINE | ID: mdl-26273677

ABSTRACT

AIM: To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM). MATERIAL AND METHODS: A total of 61 adults with type 1 DM were randomly and prospectively assigned in open-label fashion to take insulin and rosiglitazone 4 mg/day (n = 30) or insulin alone (n = 31) for a period of 18 weeks while undergoing insulin therapy without acute metabolic complications. RESULTS: Combination therapy did not significantly improve metabolic and inflammatory parameters, insulin sensitivity, and adiponectin levels. While leptin and resistin levels decreased in both groups (group 1: resistin 6.96 ± 3.06 to 4.99 ± 2.64, P = 0.006; leptin 25.8 ± 17.6 to 20.1 ± 12.55, P = 0.006; group 2: resistin 7.16 ± 2.30 to 5.57 ± 2.48, P = 0.031; leptin 16.72 ± 16.1 to 14.0 ± 13.4, P = 0.007) Hgb and fibrinogen levels decreased only in group 1 (Hgb 13.72 ± 1.98 to 13.16 ± 1.98, P = 0.015, and fibrinogen 4.00 ± 1.08 to 3.46 ± 0.90, P = 0.002). Patients in both groups showed weight gain and the incidence of hypoglycemia was not lower. DISCUSSION: The diverse favorable effects of TZDs were not fully experienced in patients with type 1 DM. These results are suggesting that insulin sensitizing and anti-inflammatory characteristics of TZDs were likely to be more pronounced in patients who were not totally devoid of endogenous insulin secretion.


Subject(s)
Adipokines/blood , Diabetes Mellitus, Type 1/blood , Drug Therapy, Combination , Inflammation/drug therapy , Insulin/administration & dosage , Thiazolidinediones/administration & dosage , Adiponectin/metabolism , Adult , Aged , Blood Glucose/metabolism , Diabetes Mellitus, Type 1/drug therapy , Enzyme-Linked Immunosorbent Assay , Female , Fibrinogen/metabolism , Humans , Hyperglycemia/blood , Hypoglycemic Agents/therapeutic use , Insulin/metabolism , Insulin Secretion , Leptin/blood , Male , Middle Aged , Prognosis , Prospective Studies , Resistin/blood , Rosiglitazone , Young Adult
12.
Psychiatry Clin Neurosci ; 69(11): 699-707, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26172069

ABSTRACT

AIMS: In the present study, our aim was to investigate the oxidative-antioxidative systems in unmedicated first-episode psychosis (FEP) patients at the beginning and after short-term treatment. METHODS: This study consisted of 29 patients who experienced an FEP and 25 control subjects. In order to investigate the oxidative status, we determined plasma malondialdehyde (MDA) levels, oxidizability of red blood cells, oxidation and oxidizability of apolipoprotein B-containing lipoproteins (apo B-basal MDA and apo B-ΔMDA). In order to evaluate the antioxidative defense, we measured serum total antioxidative capacity, uric acid, albumin, total bilirubin and vitamin E levels and serum paraoxonase/arylesterase, whole blood glutathione peroxidase (GPx) and red blood cell superoxide dismutase activities before and after 6 weeks of treatment in patients with FEP. RESULTS: Plasma MDA and apo B-basal MDA levels and red blood cell superoxide dismutase activity were significantly higher and serum arylesterase and whole blood-GPx activities were lower in the FEP group than those of the healthy control group. There were not any significant changes in the oxidative and antioxidative system parameters (except increased vitamin E levels) after treatment. CONCLUSIONS: The results of this study suggest that FEP is accompanied by oxidative stress. However, further studies are needed to clarify the role of oxidative stress in the physiopathologic mechanisms of FEP, so that oxidative and antioxidative system parameters can be used in the management of these patients. In accordance with psychiatric evaluation, for a better management, patients with FEP may require a multidisciplinary approach, including oxidative and antioxidative system parameters.


Subject(s)
Antipsychotic Agents/pharmacology , Oxidative Stress/drug effects , Psychotic Disorders/drug therapy , Psychotic Disorders/metabolism , Adult , Antipsychotic Agents/therapeutic use , Apolipoprotein B-100/blood , Aryldialkylphosphatase/blood , Bilirubin/blood , Carboxylic Ester Hydrolases/blood , Case-Control Studies , Erythrocytes/metabolism , Female , Glutathione Peroxidase/blood , Humans , Male , Malondialdehyde/blood , Oxidation-Reduction , Psychotic Disorders/blood , Psychotic Disorders/diagnosis , Serum Albumin/metabolism , Serum Albumin, Human , Superoxide Dismutase/blood , Uric Acid/blood , Vitamin E/blood , Young Adult
13.
Eur Cytokine Netw ; 26(4): 73-8, 2015.
Article in English | MEDLINE | ID: mdl-26967765

ABSTRACT

This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome (PCOS). A total of 37 premenopausal PCOS patients with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy volunteers (n = 18, mean (SD) age:29.8 (4.1) years) were included in this study. Data on clinical characteristics, glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR. In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels among PCOS patients in terms of co-morbid obesity and in comparison to controls.


Subject(s)
Cytokines/blood , Insulin Resistance , Nicotinamide Phosphoribosyltransferase/blood , Obesity/blood , Obesity/complications , Polycystic Ovary Syndrome/blood , Polycystic Ovary Syndrome/complications , Resistin/blood , Adult , Case-Control Studies , Female , Humans , Insulin/blood , Lipids/blood , Young Adult
14.
ScientificWorldJournal ; 2014: 351598, 2014.
Article in English | MEDLINE | ID: mdl-25431786

ABSTRACT

The purpose of this study was to investigate the effects of vitamin B6 (Vit B6) on oxidant and antioxidant status in streptozotocin-induced diabetic rats. Thirty-two Wistar rats were divided into four groups: control (C), control + Vit B6 group (C + Vit B6), diabetes (D), and diabetes + Vit B6 group (D + Vit B6). Vit B6 (4 mg/kg body weight) was administered in drinking water for 4 weeks after the induction of diabetes. Vitamin B6 reduced serum total cholesterol level in the C + Vit B6 (P < 0.01) and D + Vit B6 (P < 0.05) groups. Plasma and tissue malondialdehyde levels were reduced in the C + Vit B6 and D + Vit B6 groups. Whole blood glutathione peroxidase (GSH-Px) and erythrocyte superoxide dismutase (SOD) activities were higher in the D group (P < 0.05). GSH-Px and SOD activities were increased in C + Vit B6 group while these parameters decreased in the D + Vit B6 group. Paraoxonase and arylesterase activities were decreased in the D group while they were increased in C + Vit B6 and D + Vit B6 groups. The results of present study suggest that vitamin B6 supplementation might be a promising adjunctive agent for improving oxidative stress and metabolic disturbances and for preventing diabetic complications including atherogenesis.


Subject(s)
Antioxidants/pharmacology , Aryldialkylphosphatase/blood , Carboxylic Ester Hydrolases/blood , Diabetes Mellitus, Experimental/drug therapy , Vitamin B 6/pharmacology , Administration, Oral , Animals , Atherosclerosis/prevention & control , Cholesterol/blood , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/enzymology , Drug Administration Schedule , Enzyme Activation/drug effects , Erythrocytes/chemistry , Erythrocytes/drug effects , Erythrocytes/enzymology , Glutathione Peroxidase/blood , Male , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Rats , Rats, Wistar , Streptozocin , Superoxide Dismutase/metabolism
15.
Acta Neuropsychiatr ; 26(5): 291-7, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25241757

ABSTRACT

OBJECTIVE: The aim of the current study is to determine whether serum levels of brain-derived neurotrophic factor (BDNF) and interleukin-2 (IL-2) can be biological indicators for the diagnosis of schizophrenia in patients with depressive symptoms. METHOD: Forty-seven patients (11 patients diagnosed with schizophrenia, 16 patients diagnosed with schizophrenia and comorbid depression and 20 patients diagnosed with major depressive disorder) and 20 healthy subjects were enrolled. The Positive and Negative Symptoms Scale, the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale were used for assessment. The serum BDNF and IL-2 levels of all the subjects were studied. RESULTS: Decreased levels of serum BDNF and increased levels of serum IL-2 were found in the patients diagnosed with either schizophrenia, schizophrenia with depression, or major depressive disorder (p = 0.049, p = 0.010; p = 0.001 and p = 0.044; p = 0.027, p = 0.003; respectively) compared with control group. There were no significant differences between the patient groups in their serum BDNF and IL-2 levels. CONCLUSIONS: The present study suggests that neurotrophic factors and immune system changes are involved in the pathogenesis of schizophrenia with or without depressive symptomatology. However, the data do not clarify whether depressive symptoms in schizophrenia occur as a dimension of schizophrenia or as symptoms of major depression that is comorbid with schizophrenia.


Subject(s)
Brain-Derived Neurotrophic Factor/blood , Depressive Disorder/blood , Depressive Disorder/diagnosis , Interleukin-2/blood , Schizophrenia/blood , Adult , Biomarkers/blood , Case-Control Studies , Depressive Disorder/complications , Depressive Disorder, Major/blood , Depressive Disorder, Major/complications , Depressive Disorder, Major/diagnosis , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Schizophrenia/complications
16.
Acta Cardiol ; 69(4): 399-405, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25181915

ABSTRACT

OBJECTIVE: Inflammation and dystrophic calcification have been associated with cardiovascular disease (CVD) and chronic heart failure (CHF). The aim of the present study was to investigate the potential usefulness of fetuin-A as a biomarker in CHF. METHODS: Serum fetuin-A was measured in 66 CHF patients with left ventricular function < 50% and in 31 healthy controls at baseline. Fetuin-A was evaluated as a diagnostic marker for systolic heart failure and compared with C-reactive protein (CRP) and pro-brain natriuretic peptide (pro-BNP). RESULTS: The levels of serum fetuin-A were significantly decreased in the CHF patients compared to the control group (P < 0.01). Although there were significant correlations between fetuin-A and certain parameters in patients and controls, none of these were present consistently in either group. It was found that serum fetuin-A levels could identify patients with systolic heart failure with a high degree of sensitivity and specificity. CONCLUSIONS: Serum fetuin-A is decreased in CHF patients, indicating that anti-inflammatory activity is downregulated in CHF and that calcification may be associated with CHF.


Subject(s)
Heart Failure, Systolic/diagnosis , alpha-2-HS-Glycoprotein/metabolism , Aged , Biomarkers/blood , C-Reactive Protein/metabolism , Case-Control Studies , Female , Heart Failure, Systolic/blood , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Predictive Value of Tests , Sensitivity and Specificity , Severity of Illness Index , Ventricular Dysfunction, Left/diagnosis
17.
World J Gastroenterol ; 19(44): 8065-70, 2013 Nov 28.
Article in English | MEDLINE | ID: mdl-24307801

ABSTRACT

AIM: To evaluate the effects of disease severity and necrosis on organ dysfunctions in acute pancreatitis (AP). METHODS: One hundred and nine patients treated as AP between March 2003 and September 2007 with at least 6 mo follow-up were included. Patients were classified according to severity of the disease, necrosis ratio and localization. Subjective clinical evaluation and fecal pancreatic elastase-I (FPE-I) were used for exocrine dysfunction evaluation, and oral glucose tolerance test was completed for endocrine dysfunction. The correlation of disease severity, necrosis ratio and localization with exocrine and endocrine dysfunction were investigated. RESULTS: There were 58 male and 51 female patients, and mean age was 56.5 ± 15.7. Of the patients, 35.8% had severe AP (SAP) and 27.5% had pancreatic necrosis. Exocrine dysfunction was identified in 13.7% of the patients [17.9% were in SAP, 11.4% were in mild AP (MAP)] and 34.7% of all of the patients had endocrine dysfunction (56.4% in SAP and 23.2% in MAP). In patients with SAP and necrotizing AP (NAP), FPE-Ilevels were lower than the others (P < 0.05 and 0.001 respectively) and in patients having pancreatic head necrosis or near total necrosis, FPE-1 levels were lower than 200 µg/g stool. Forty percent of the patients who had undergone necrosectomy developed exocrine dysfunction. Endocrine dysfunction was more significant in patients with SAP and NAP (P < 0.001). All of the patients in the necrosectomy group had endocrine dysfunction. CONCLUSION: Patients with SAP, NAP, pancreatic head necrosis and necrosectomy should be followed for pancreatic functions.


Subject(s)
Pancreas/pathology , Pancreatitis, Acute Necrotizing/diagnosis , Adult , Aged , Aged, 80 and over , Carrier Proteins/metabolism , Clinical Enzyme Tests , Exocrine Pancreatic Insufficiency/complications , Exocrine Pancreatic Insufficiency/diagnosis , Feces/chemistry , Female , Glucose Tolerance Test , Humans , Male , Middle Aged , Necrosis , Pancreas/diagnostic imaging , Pancreas/metabolism , Pancreas/surgery , Pancreatectomy/adverse effects , Pancreatic Elastase , Pancreatic Function Tests , Pancreatitis, Acute Necrotizing/metabolism , Pancreatitis, Acute Necrotizing/pathology , Pancreatitis, Acute Necrotizing/surgery , Predictive Value of Tests , Severity of Illness Index , Time Factors , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
18.
Ther Adv Psychopharmacol ; 2(2): 65-74, 2012 Apr.
Article in English | MEDLINE | ID: mdl-23983958

ABSTRACT

OBJECTIVE: Brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and leptin have been hypothesized to be involved in the neurobiology of depression. The aim of this study was to investigate BDNF, VEGF and leptin levels in patients with severe melancholic depression. METHODS: A total of 40 drug-free patients with major depressive disorder (MDD) with melancholic features and 40 healthy controls were included in the study. Demographic information, psychiatric evaluation and physical examination were documented for both groups. Serum BDNF, VEGF levels were determined by enzyme-linked immunosorbent assay and leptin with radioimmunoassay methods. The Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were applied to the patients. RESULTS: There were no significant differences in serum BDNF, VEGF and leptin levels between the patient and control groups. There was a negative correlation between BDNF levels and the number of depressive episodes. It was noted that VEGF levels decreased with increasing severity of depression. CONCLUSIONS: These findings suggest that BDNF levels might be associated with the recurrence of depression and VEGF levels might be a determinant of the severity of depression.

19.
Diabetes Res Clin Pract ; 94(2): 212-6, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21855160

ABSTRACT

AIM: Sitagliptin is not associated with weight gain and has neutral effects on body weight. It is unclear whether sitagliptin treatment alters serum ghrelin levels in people with type 2 diabetes. METHODS: Forty-four subjects with type 2 diabetes were randomly assigned to receive sitagliptin or medical nutrition therapy (MNT) for 12 weeks. Changes in anthropometric variables, glycemic control, insulin resistance, lipid parameters, and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment. RESULTS: Significant decreases in body weight and body mass index were observed over the entire study period in both treatment groups. Glycosylated hemoglobin and postprandial plasma glucose levels were statistically significant decreased in the groups receiving sitagliptin compared with baseline values (p=0.021 and p=0.021, respectively), while they were unchanged in the groups receiving MNT. There was a significant decrease in total ghrelin in the groups receiving sitagliptin (p=0.04) compared with baseline values but not in the groups receiving MNT (p=0.46) at the end of the 12 weeks. CONCLUSIONS: In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels. These results suggest that the neutral effect of sitagliptin on weight might be associated with the suppression of fasting serum ghrelin levels.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Ghrelin/blood , Hypoglycemic Agents/therapeutic use , Pyrazines/therapeutic use , Triazoles/therapeutic use , Aged , Analysis of Variance , Biomarkers/blood , Blood Glucose/drug effects , Blood Glucose/metabolism , Body Mass Index , Body Weight/drug effects , Chi-Square Distribution , Diabetes Mellitus, Type 2/blood , Down-Regulation , Female , Glycated Hemoglobin/metabolism , Humans , Lipids/blood , Male , Middle Aged , Sitagliptin Phosphate , Time Factors , Treatment Outcome , Turkey
20.
Prog Neuropsychopharmacol Biol Psychiatry ; 35(5): 1284-90, 2011 Jul 01.
Article in English | MEDLINE | ID: mdl-21515329

ABSTRACT

PURPOSE: Major depressive disorder (MDD) is a devastating disease that afflicts large populations and has also been accepted to be an independent risk factor for cardiovascular disease (CVD). Oxidative stress seems to play an essential role in the relationship of MDD and CVD. We aimed to determine the level of oxidative stress in patients with MDD and to investigate the effects of long-term antidepressant (AD) treatment on the oxidative-antioxidative system parameters and CVD risk factors. METHOD: Fifty patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for MDD and 44 healthy control subjects were included in the study. Control visits of the patients were repeated 6weeks, 12weeks and 24weeks after beginning of the AD treatment. Lipid profiles, oxidation and oxidizability of apolipoprotein B-containing lipoproteins (expressed as apo B-b-MDA and apo B-Δ-MDA, respectively), levels of plasma malondialdehyde (p-MDA), total antioxidative capacity (TAOC), antioxidant molecules and antioxidant enzyme activities including paraoxonase/arylesterase, red blood cell superoxide dismutase (RBC-SOD) and glutathione peroxidase were determined during 24-week of follow-up period. RESULTS: According to the results of the study, p-MDA, apo B-b-MDA and RBC-SOD activity were increased and arylesterase activity was decreased in MDD patients. Body mass index (BMI), vitamin A and total cholesterol levels in MDD patients increased after 24-weeks of AD treatment. RBC-SOD activity, TAOC, p-MDA and apo B-b-MDA levels were decreased; paraoxonase/arylesterase activities and apo B-Δ-MDA were increased at the end of 24th week. CONCLUSION: Oxidative stress, demonstrated in MDD patients, was partly improved during 24weeks of AD treatment. Increase in paraoxonase/arylesterase activities and decrease in p-MDA and apo B-b-MDA levels after 24weeks seem to be beneficial for reduction of CVD risk in MDD patients. However increased BMI and apo B-Δ-MDA levels are negative cardiovascular effects of long-term AD treatment.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder, Major/drug therapy , Oxidative Stress/drug effects , Adult , Antidepressive Agents/adverse effects , Antioxidants/metabolism , Apolipoproteins/blood , Aryldialkylphosphatase/metabolism , Blood Cell Count , Body Mass Index , Carboxylic Ester Hydrolases/metabolism , Cardiovascular Diseases/drug therapy , Depressive Disorder, Major/diagnosis , Female , Follow-Up Studies , Hormones/blood , Humans , Lipids/blood , Liver Function Tests , Long-Term Care , Male , Malondialdehyde/blood , Psychiatric Status Rating Scales , Risk Factors , Superoxide Dismutase/blood , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...